Package Leaflet: Information for the Patient
Corlentor 5 mg film-coated tablets
Corlentor 7.5 mg film-coated tablets
ivabradine
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack and other information
Corlentor (ivabradine) is a heart medicine used to treat:
Symptomatic stable angina (which causes chest pain) in adult patients whose heart rate is greater than or equal to 70 beats per minute. It is used in adult patients who do not tolerate or cannot take heart medicines called beta-blockers. It is also used in combination with beta-blockers in adult patients whose disease is not fully controlled with a beta-blocker.
Chronic heart failure in adult patients whose heart rate is greater than or equal to 75 beats per minute. It is used in combination with standard treatment, including treatment with beta-blockers, or when beta-blockers are contraindicated or not tolerated.
About stable angina:
Stable angina is a heart disease that occurs when the heart does not receive enough oxygen. The most common symptom of angina is pain or discomfort in the chest.
About chronic heart failure:
Chronic heart failure is a heart disease that occurs when your heart cannot pump enough blood to the rest of your body. The most common symptoms of heart failure are difficulty breathing, fatigue, tiredness, and swelling of the ankles.
How does Corlentor work?
The specific heart rate lowering action of Corlentor helps to:
Do not take Corlentor
Warnings and precautions
Talk to your doctor or pharmacist before taking Corlentor:
If you meet any of these conditions, consult your doctor immediately before or during treatment with Corlentor.
Children
Do not give this medicine to children and adolescents under 18 years of age. The available data are insufficient in this age group.
Using Corlentor with other medicines
Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.
Make sure to inform your doctor if you are taking any of the following medicines, as a dose adjustment of Corlentor or monitoring may be necessary:
Taking Corlentor with food and drinks
Avoid grapefruit juice during treatment with Corlentor.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Do not take Corlentor if you are pregnant or planning to become pregnant (see "Do not take Corlentor").
If you are pregnant and have taken Corlentor, talk to your doctor.
Do not take Corlentor if you are of childbearing age and are not using reliable contraceptive methods (see "Do not take Corlentor").
Do not take Corlentor if you are breast-feeding (see "Do not take Corlentor"). Talk to your doctor if you are breast-feeding or planning to breast-feed, as breast-feeding should be stopped if you are taking Corlentor.
Driving and using machines
Corlentor may cause transient visual luminous phenomena (a transient brightness in the field of vision, see "Possible side effects"). If this happens, be careful when driving or using machinery in situations where sudden changes in light intensity may occur, especially when driving at night.
Corlentor contains lactose
If your doctor has told you that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Always take this medicine exactly as your doctor or pharmacist has told you. If you are not sure, check with your doctor or pharmacist.
Corlentor should be taken with breakfast and dinner.
Corlentor 5 mg tablets can be divided into equal doses
If you are being treated for stable angina
The initial dose should not exceed one Corlentor 5 mg tablet twice a day. If you still have symptoms of angina and if you have tolerated the 5 mg twice daily dose well, the dose may be increased. The maintenance dose should not exceed 7.5 mg twice a day. Your doctor will prescribe the correct dose for you. The usual dose is one tablet in the morning and one tablet in the evening. In some cases (for example, if you are 75 years or older), your doctor may prescribe half the dose, i.e. half a Corlentor 5 mg tablet (corresponding to 2.5 mg of ivabradine) in the morning and half a 5 mg tablet in the evening.
If you are being treated for chronic heart failure
The recommended initial dose is one Corlentor 5 mg tablet twice a day, which may be increased if necessary to one Corlentor 7.5 mg tablet twice a day. Your doctor will decide the suitable dose for you. The usual dose is one tablet in the morning and one tablet in the evening. In some cases (for example, if you are 75 years or older), your doctor may prescribe half the dose, i.e. half a Corlentor 5 mg tablet (corresponding to 2.5 mg of ivabradine) in the morning and half a 5 mg tablet in the evening.
If you take more Corlentor than you should:
An overdose of Corlentor may make you feel tired or have difficulty breathing because your heart is beating too slowly. If this happens, contact your doctor immediately.
If you forget to take Corlentor:
If you forget to take a dose of Corlentor, take the next dose at the scheduled time. Do not take a double dose to make up for forgotten doses.
The calendar printed on the blister pack containing the tablets will help you remember when you last took a Corlentor tablet.
If you stop taking Corlentor:
Generally, treatment of angina or chronic heart failure is lifelong, so you should consult your doctor before stopping this medicine.
If you think that the action of Corlentor is too strong or too weak, talk to your doctor or pharmacist.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The most common side effects with this medicine are dose-dependent and related to its mechanism of action:
Very common(may affect more than 1 in 10 people)
Transient visual luminous phenomena (brief moments of increased brightness, usually caused by sudden changes in light intensity). They can also be described as a halo, flashes of color, image decomposition, or multiple images. These usually appear during the first two months of treatment after which they may occur repeatedly and resolve during or after treatment.
Common(may affect up to 1 in 10 people)
Modification of heart function (symptoms are a slowing of the heart rate). This occurs especially in the first 2 to 3 months after starting treatment.
Other side effects have also been reported:
Common(may affect up to 1 in 10 people)
Irregular rapid heart contraction (atrial fibrillation), sensation of abnormal heartbeat (bradycardia, ventricular extrasystoles, 1st degree AV block (prolongation of the PQ interval on the ECG)), uncontrolled high blood pressure, headache, dizziness, and blurred vision (cloudy vision).
Uncommon(may affect up to 1 in 100 people)
Palpitations and extra heartbeats, sensation of dizziness (nausea), constipation, diarrhea, abdominal pain, sensation of spinning (vertigo), difficulty breathing (dyspnea), muscle spasms, elevated blood uric acid levels, an excess of eosinophils (a type of white blood cell) and elevated creatinine levels in the blood (a muscle breakdown product), skin rash, angioedema (such as inflammation of the face, tongue, or throat, difficulty breathing or swallowing), low blood pressure, fainting, feeling of tiredness, feeling of weakness, abnormal electrocardiogram, double vision, visual disturbance.
Rare(may affect up to 1 in 1,000 people) Urticaria, itching, skin redness, malaise.
Very rare(may affect up to 1 in 10,000 people)
Irregular heartbeats (2nd degree AV block, 3rd degree AV block, sick sinus syndrome).
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton, after EXP. The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of Corlentor
Corlentor 5 mg film-coated tablets:
Each film-coated tablet contains 5 mg of ivabradine (as hydrochloride).
Corlentor 7.5 mg film-coated tablets:
Each film-coated tablet contains 7.5 mg of ivabradine (as hydrochloride).
Tablet core: lactose monohydrate, magnesium stearate (E 470 B), corn starch, maltodextrin, colloidal anhydrous silica (E 551),
Coating: hypromellose (E 464), titanium dioxide (E 171), macrogol 6000, glycerol (E 422), magnesium stearate (E 470 B), yellow iron oxide (E 172), red iron oxide (E 172).
Appearance and Packaging of the Product
Corlentor 5 mg tablets are film-coated, salmon-colored, oblong, scored on both sides, engraved with "5" on one side and on the other.
Corlentor 7.5 mg tablets are film-coated, salmon-colored, triangular, engraved with "7.5" on one side and on the other.
The tablets are presented in calendar packs (aluminum/PVC blisters) of 14, 28, 56, 84, 98, 100, or 112 tablets.
Not all presentations may be marketed.
Marketing Authorization Holder
Les Laboratoires Servier
50, rue Carnot
92284 Suresnes cedex - France
Manufacturer
Les Laboratoires Servier Industrie
905 route de Saran
45520 Gidy - France
Servier (Ireland) Industries Ltd
Gorey Road
Arklow - Co. Wicklow - Ireland
Przedsiebiorstwo Farmaceutyczne ANPHARM S.A. ul.
Annopol 6B – 03-236 Warszawa – Poland
Laboratorios Servier, S.L.
Avda. de los Madroños, 33
28043 Madrid
Spain
You can request more information about this medication by contacting the local representative of the marketing authorization holder.
België/Belgique/Belgien S.A. Servier Benelux N.V. Tél/Tel: +32 (0)2 529 43 11 | Lietuva UAB ”SERVIER PHARMA” Tel: +370 (5) 2 63 86 28 |
Luxembourg/Luxemburg S.A. Servier Benelux N.V. Tél/Tel: +32 (0)2 529 43 11 | |
Ceská republika Servier s.r.o. Tel: +420 222 118 111 | Magyarország Servier Hungaria Kft. Tel.: + 36 1 238 77 99 |
Danmark Servier Danmark A/S Tlf: +45 36 44 22 60 | Malta V.J. Salomone Pharma Ltd Tel: + 356 21 22 01 74 |
Deutschland Servier Deutschland GmbH Tel: +49 (0)89 57095 01 | Nederland Servier Nederland Farma B.V. Tel: +31 (0)71 5246700 |
Eesti Servier Laboratories OÜ Tel:+ 372 664 5040 | Norge Servier Danmark A/S Tlf: +45 36 44 22 60 |
Ελλάδα ΣΕΡΒΙΕ ΕΛΛΑΣ ΦΑΡΜΑΚΕΥΤΙΚΗ ΕΠΕ Τηλ: +30 210 939 1000 | Österreich Servier Austria GmbH Tel: +43 (1) 524 39 99 |
España DANVAL S.A. Tel: +34 91 748 96 30 | Polska Servier Polska SP. Z O.O. Tel.: + 48 (0) 22 594 90 00 |
France Les Laboratoires Servier Tél: +33 (0)1 55 72 60 00 | Portugal Servier Portugal, Lda Tel: +351 21 312 20 00 |
Hrvatska Servier Pharma, d. o. o. Tel.: +385 (0)1 3016 222 | România Servier Pharma SRL Tel: +4 021 528 52 80 |
Ireland Servier Laboratories (Ireland) Ltd. Tel: +353 (0)1 663 8110 | Slovenija Servier Pharma d.o.o. Tel: + 386 (0)1 563 48 11 |
Ísland Servier Laboratories C/o Icepharma hf Sími: +354 540 8000 | Slovenská republika Servier Slovensko spol. s r.o. Tel: +421 (0) 2 5920 41 11 |
Italia Istituto Farmaco Biologico Stroder S.r.l. Tel: +39 06 669081 | Suomi/Finland Servier Finland Oy P./Tel: +358 (0)9 279 80 80 |
Κύπρος C.A. Papaellinas Ltd. Τηλ: +357 22741741 | Sverige Servier Sverige AB Tel: +46(8)5 225 08 00 |
Latvija SIA Servier Latvia Tel: + 371 67502039 | United Kingdom (Northern Ireland) Servier Laboratories (Ireland) Ltd Tel: +44 (0)1753 666409 |
Date of Last Revision of this Leaflet:
Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu.